A Study of the Safety and Efficacy of MK-0431A XR, a Fixed-Dose Combination Tablet of Sitagliptin and Extended-Release Metformin in Pediatric Participants aged 10-17 years With Type 2 Diabetes Mellitus - Trial SLCTR_2014_037
Access comprehensive clinical trial information for SLCTR_2014_037 through Pure Global AI's free database. This Phase 3 trial is sponsored by Merck Sharp and Dohme Corp and is currently Completed. The study focuses on Type 2 Diabetes Mellitus.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Sri Lanka Clinical Trials Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
SLCTR_2014_037
Phase 3
Completed
Trial Details
Sri Lanka Clinical Trials Registry • SLCTR_2014_037
A Study of the Safety and Efficacy of MK-0431A XR, a Fixed-Dose Combination Tablet of Sitagliptin and Extended-Release Metformin in Pediatric Participants aged 10-17 years With Type 2 Diabetes Mellitus
A Phase III Multicenter, Double-Blind, Randomized, Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A XR (a Fixed-Dose Combination Tablet of Sitagliptin and Extended-Release Metformin) in Pediatric Subjects aged 10-17 years with Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Study Focus
Interventional
Sponsor & Location
Merck Sharp and Dohme Corp
Australia, Brazil, Bulgaria, Canada, Chile, Colombia, Costa Rica, Czech Republic, Denmark, Georgia,
Timeline & Enrollment
Phase 3
Jan 05, 2015
N/A
ICD-10 Classifications
Type 2 diabetes mellitus
Type 2 diabetes mellitus with unspecified complications
Type 2 diabetes mellitus with other specified complications
Type 2 diabetes mellitus without complications
Type 2 diabetes mellitus with multiple complications
Data Source
Sri Lanka Clinical Trials Registry
SLCTR_2014_037
Non-Device Trial